Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

NCT01084330 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastric Cancer
Gastro-esophageal Junction Cancer

Interventions

DRUG: AUY922
DRUG: Docetaxel
DRUG: Irinotecan

Sponsor

Novartis Pharmaceuticals